Life Sciences
Top stories summarized by our editors
8/22/2017

Brent Erickson, BIO executive vice president and head of the Industrial Biotechnology section, speaks out in favor of the Renewable Fuel Standard in this op-ed column. "Rather than subject the RFS to attempts at legislative reforms in an uncertain political environment, we should instead push EPA for correct and timely implementation of the RFS, a strategy with which we have seen success," Erickson writes.

Full Story:
Biofuels Digest
8/22/2017

Financing worth $8 million was secured by Carmel, Ind.-based medtech company FAST BioMedical from the NIH and a single family office investor. The company, which makes technologies for measuring kidney function and blood volume, intends to use the money for completion of its next human trial and to hire additional employees.

More Summaries:
FAST BioMedical, NIH
8/22/2017

Carl Zeiss Meditec paid an undisclosed amount for Veracity Innovations, a cloud-based ophthalmological technology developer. Veracity's surgical planning platform, which enables direct interface with diagnostic devices and EMRs, is expected to complement the Zeiss Forum system, one of Zeiss' digital solutions that aids in clinical decision-making and data management.

Full Story:
MassDevice (Boston)
8/22/2017

An agreement was reached by Laboratory Corp. of America with OmniSeq to exclusively distribute OmniSeq's immune profiling and pan-cancer next-generation sequencing tests. Under the deal, LabCorp will be an investor in OmniSeq's round of Series B financing, while OmniSeq will be responsible for performing the assays and offering the products worldwide through Covance Drug Development and in the US via Integrated Oncology.

More Summaries:
OmniSeq, LabCorp
8/22/2017

Australian medtech firm Anatomics entered into a deal with Singapore's Nanyang Technological University to accelerate research and development of smart implants and 3D-printing materials for medical devices. A partnership has also been reached by Anatomics with Singapore-based manufacturing firm Ultra Clean Technologies to commercialize its 3D-printed medical devices in the Asian market.

Full Story:
3Ders (Netherlands)
8/22/2017

A series of reports from iData Research predicts the US market for orthopedic small bone and joint devices will hit $4 billion by 2023. The largest share of the market is held by DePuy Synthes because of its position in the plate and screw and external fixation device markets.

Full Story:
Becker's Spine Review
More Summaries:
DePuy Synthes, iData Research
8/22/2017

The FDA has granted BioVentrix an investigational device exemption approval to conduct a trial evaluating the safety and efficacy of its Revivent TC transcatheter ventricular enhancement system, which is intended for treating patients with ischemic cardiomyopathy. The first patient in the 120-patient trial, which seeks to include up to 20 US and UK sites, has been enrolled and has undergone procedure at Papworth Hospital in the UK.

Full Story:
MassDevice (Boston)
More Summaries:
FDA, BioVentrix
8/22/2017

European regulators have given Medtronic CE mark approval for its Attain Stability Quad MRI SureScan left heart lead, a device intended for use in cardiac resynchronization therapy to allow for precise lead placement and stability in patients with heart failure. The company has already begun a limited commercial release of the device in Europe and has recorded the first implantations of the device at a Norwegian hospital.

More Summaries:
Medtronic, Norwegian hospital
8/22/2017

Novartis' ad campaign for its systemic juvenile idiopathic arthritis drug Ilaris features a child running through a field with outstretched arms preparing to "take off" with playful text reading, "Today he's not thinking about SJIA," is among six campaigns featured for creatively blending art and copy to convey an informative, inspiring message. Others include Shire's "How's iit going" campaign for dry eye treatment Xiidra and Sanofi's depiction of angiogenesis wrapping around the word "EVOLVE" to illustrate its Zaltrap metastatic colorectal cancer drug.

More Summaries:
Novartis, Sanofi, Shire, Xiidra
8/22/2017

Dr. Reddy's Laboratories is overhauling marketing campaigns for brands including Doan's and Bufferin, which the firm acquired from Ducere Pharma last year. In addition to TV ads, the Doan's campaign includes an updated website and digital and search placements, which are getting positive results, according to OTC brand marketing director Lauren Schulz.

Full Story:
FiercePharma
More Summaries:
Dr. Reddy